Ehrlichiosis in Dogs — Management Guide

Comprehensive clinical guide to canine ehrlichiosis: causes, stages (acute, subclinical, chronic), diagnosis, doxycycline treatment, pancytopenia, German Shepherd risk, and long-term care.

Quick overview

• What it is: Ehrlichiosis in dogs is a tick‑borne infection most commonly caused by Ehrlichia canis (a bacterial organism) that infects white blood cells and bone marrow. It produces a spectrum from short-lived acute illness to a subclinical carrier state and, in some dogs, a life‑threatening chronic disease with bone‑marrow failure (pancytopenia).
• Who's at risk: Dogs in areas with brown dog ticks (Rhipicephalus sanguineus) or other tick vectors, dogs with poor tick control, hunting/working dogs, and certain breeds — notably German Shepherds — which are predisposed to severe, chronic disease.
• Prognosis: Good when recognized and treated in the acute or subclinical phase; guarded to poor in chronic cases that have developed severe bone marrow suppression and pancytopenia.

This guide is for educational purposes. Always consult your veterinarian for diagnosis and treatment.

Pathophysiology — explained simply

Ehrlichia canis is transmitted by infected ticks. After a bite, the organism enters and multiplies within monocytes/macrophages (white blood cells) and can seed the bone marrow and spleen. The host response determines outcome:

• Acute phase: bacteria multiply, immune activation causes fever, lethargy, and platelet consumption.
• Subclinical phase: immune system partially controls the infection; bacteria may persist at low levels without obvious signs.
• Chronic phase: ongoing infection and immune dysregulation can cause bone marrow suppression, immune‑mediated destruction of blood cells, and progressive loss of red cells, white cells and platelets (pancytopenia). This leads to weakness, bleeding, susceptibility to secondary infections and can be refractory to treatment if marrow damage is advanced.

Breed‑specific risk factors and prevalence

• Vector exposure (brown dog tick) is the dominant risk factor; prevalence correlates with tick distribution.
• German Shepherds have a well‑recognized predisposition to severe, chronic manifestations, including aplastic or hypoplastic bone marrow and marked pancytopenia. These dogs are more likely to develop refractory disease and poorer outcomes.
• Working/hunting breeds and dogs in endemic regions (southern U.S., Mediterranean, parts of Africa, Asia, and Latin America) show higher seroprevalence.

Clinical signs and stages

Canine ehrlichiosis is classically divided into three phases. Signs may overlap and individual dogs vary.

Acute phase (1–3 weeks post‑infection)

• Fever, lethargy, inappetence
• Lymphadenopathy, ocular discharge
• Mild anemia and thrombocytopenia on bloodwork (thrombocytopenia is the most common lab abnormality)
• Some recover completely with treatment; others progress to subclinical phase

Subclinical phase (weeks to months to years)

• Dog appears clinically normal or has intermittent, vague signs (weight loss, waxing and waning activity)
• Organism persists at low levels; dogs can relapse or progress, especially under stress or immune suppression

Chronic phase (months to years)

• Marked lethargy, weight loss, muscle wasting
• Persistent fever is less common; bleeding (petechiae, ecchymoses, mucosal bleeding) due to thrombocytopenia
• Recurrent infections because of neutropenia
• Pancytopenia: concurrent severe anemia, neutropenia and thrombocytopenia from bone marrow failure or severe immune‑mediated destruction
• In severe chronic cases (especially in predisposed German Shepherds), marrow aplasia may be irreversible and prognosis is guarded to poor

Diagnostic approach

A stepwise diagnostic approach combines history, physical examination, hematology, and targeted tests.

Initial diagnostics

• CBC (complete blood count): look for thrombocytopenia (very common), anemia (regenerative or non‑regenerative), leukopenia or neutropenia. Pancytopenia suggests chronic marrow involvement.
• Blood smear: may rarely show Ehrlichia morulae within monocytes in acute infections (low sensitivity).
• Serum biochemistry: may show hyperglobulinemia, elevated liver enzymes, azotemia in severe disease.
• Urinalysis: assess kidney function and proteinuria (immune complex disease can affect kidneys).

Specific tests

• Serology (IFA or ELISA antibody tests): indicates exposure. Antibodies often persist months to years after infection; a single positive test does not prove active infection but is useful when interpreted with clinical signs and bloodwork.
• PCR (polymerase chain reaction) on blood: detects organism DNA and is the best test for active infection. Sensitivity can be low in subclinical dogs or if organisms are sequestered in marrow.
• Bone marrow aspirate/biopsy: recommended when there is pancytopenia or poor response to therapy. It can show granulocytic hypoplasia, marrow infiltration, or immune‑mediated changes and helps rule out other causes (neoplasia, other infectious diseases).
• Coagulation tests (PT, aPTT) if bleeding is present.

Specialist referral

Refer to a board‑certified veterinary internal medicine specialist if:

• Pancytopenia or severe marrow abnormalities are present
• Diagnostic results are inconclusive and bone marrow biopsy is needed
• Dog is not responding to standard therapy or requires transfusions/intensive care

Treatment options

First‑line specific therapy: doxycycline

• Drug: Doxycycline (tetracycline antibiotic). It is bacteriostatic against Ehrlichia and the cornerstone of therapy.
• Typical dosing: 10 mg/kg PO once daily OR 5 mg/kg PO every 12 hours (both regimens commonly used). Administer with food to reduce GI upset. Duration: minimum 28 days (4 weeks).
• In practice, many clinicians extend treatment to 6–8 weeks or longer in chronic or persistent cases, guided by clinical response and PCR results. Because antibodies may remain positive, use PCR to help assess clearance.
• Side effects: vomiting, diarrhea, esophageal irritation if tablets lodge in the esophagus (give with water/food). Avoid in pregnant animals (teratogenic risk).

Supportive and adjunctive care

• Transfusion therapy: packed red blood cells for severe anemia; fresh whole blood or platelet‑rich products in life‑threatening bleeding (available at referral centers).
• IV fluids and nutritional support for dehydrated or anorexic dogs.
• Management of secondary infections with appropriate antibiotics when neutropenia is present.
• Immunosuppressive therapy (e.g., prednisone) may be indicated if immune‑mediated thrombocytopenia or hemolytic anemia is suspected; this is a case‑by‑case decision and often used with caution and specialist input.
• Antiemetics, gastroprotectants, and appetite stimulants as needed.

Other antimicrobial or combination therapies

• Alternatives are limited; doxycycline is preferred because of good intracellular penetration.
• Imidocarb has been reported historically but is not standard for Ehrlichia (it is primarily used for babesiosis).

Monitoring response to therapy

• Recheck CBC within 7–14 days of starting doxycycline, then every 2–4 weeks until normalization. Platelet counts often improve within 1–2 weeks in responsive dogs.
• PCR at 4–8 weeks after starting treatment can document clearance; if PCR remains positive, consider extending therapy or specialist referral.
• Serology may remain positive for months and is not reliable for cure confirmation.

Long‑term management and monitoring

• Dogs that recover from the acute phase still require follow‑up. Recheck CBC and clinical exam monthly until stable, then every 3–6 months for at least a year.
• Lifelong tick prevention is essential: topical or oral acaricides with proven efficacy against brown dog ticks, environmental control, and routine tick checks.
• Avoid immunosuppressive drugs if possible unless treating immune‑mediated complications, because they can allow relapse.
• Consider annual screening (CBC, tick prevention review) in dogs living in or traveling to endemic areas.

Prognosis and quality of life

• Acute phase: prognosis is generally good with prompt doxycycline therapy; many dogs fully recover.
• Subclinical phase: many dogs remain clinically normal but carry the organism and can relapse; prognosis for life and quality of life is usually good with monitoring and tick control.
• Chronic phase with pancytopenia: prognosis is guarded to poor. Some dogs respond partially to prolonged doxycycline and supportive care; others with severe marrow aplasia (especially German Shepherds) may not recover and may require repeated transfusions or euthanasia for poor quality of life.

Living with ehrlichiosis — practical daily tips

• Strictly follow doxycycline dosing and finish the entire prescribed course. Give with food and water to reduce GI upset.
• Protect your dog from ticks year‑round using veterinarian‑recommended topical or oral tick preventives and treating your yard/environment if infestations occur.
• Check your dog daily for ticks after outdoor activity; remove ticks promptly with fine‑point tweezers or a tick tool, grasping close to the skin and pulling straight out.
• Monitor for bleeding (nosebleeds, bruising, bloody stools), pale gums, weakness, fever, or reduced appetite — seek vet care promptly if these occur.
• Maintain a stable environment to reduce stress (which can precipitate relapse) and ensure balanced nutrition to support recovery.

When to see your vet urgently

Seek immediate veterinary care if your dog with known or suspected ehrlichiosis develops any of the following:

• Collapse, sudden weakness, difficulty standing
• Pale or very tacky (dry) gums, suggesting severe anemia or shock
• New or worsening bleeding (bleeding from gums, nose, black/tarry stools, blood in urine)
• Rapid breathing, labored breathing, or coughing
• High fever (recurrent or persistent despite treatment) or severe lethargy
• Vomiting/diarrhea leading to dehydration

Takeaway

Ehrlichiosis is a potentially treatable but sometimes persistent tick‑borne disease in dogs. Doxycycline for a minimum of 28 days is the standard of care; longer courses and supportive therapy are frequently needed in chronic cases. Pancytopenia from bone marrow suppression is the most serious chronic complication and carries a guarded prognosis — German Shepherds are at higher risk of severe, refractory disease. Close monitoring, aggressive tick prevention, and early treatment substantially improve outcomes.

Sources and further reading

• Merck Veterinary Manual: Ehrlichiosis in Dogs. Merck Veterinary Manual. https://www.merckvetmanual.com
• American College of Veterinary Internal Medicine (ACVIM): resources on vector‑borne diseases. https://www.acvim.org/
• Centers for Disease Control and Prevention (CDC): Ehrlichiosis overview (vector information). https://www.cdc.gov/ehrlichiosis/

Frequently Asked Questions